This Advances in Cancer Immunotherapy (ACI) program will be held in person at the ACR Convergence 2025 Meeting in Chicago, IL.

New for 2025

• Comprehensive overview of Immune Checkpoint Inhibitor (ICI) toxicities from both an oncologic and rheumatologic perspective.
• Discuss the evolving landscape of ICIs, their mechanisms of action, and the spectrum of toxicities encountered in clinical practice.
• Address the evaluation and management of ICI-induced rheumatic irAEs with practical insights into recognizing, diagnosing, and treating these complications to optimize patient care in a multidisciplinary setting.

Learn More